Suppr超能文献

在一系列肿瘤细胞类型中,具有抗增殖活性的螯合剂对细胞周期蛋白依赖性激酶抑制剂p21CIP1/WAF1的差异性靶向作用。

Differential targeting of the cyclin-dependent kinase inhibitor, p21CIP1/WAF1, by chelators with anti-proliferative activity in a range of tumor cell-types.

作者信息

Moussa Rayan S, Kovacevic Zaklina, Richardson Des R

机构信息

Molecular Pharmacology and Pathology Program, Discipline of Pathology and Bosch Institute, The University of Sydney, Sydney, New South Wales, 2006, Australia.

出版信息

Oncotarget. 2015 Oct 6;6(30):29694-711. doi: 10.18632/oncotarget.5088.

Abstract

Chelators such as 2-hydroxy-1-napthylaldehyde isonicotinoyl hydrazone (311) and di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone (Dp44mT) target tumor cell iron pools and inhibit proliferation. These agents also modulate multiple targets, one of which is the cyclin-dependent kinase inhibitor, p21. Hence, this investigation examined the mechanism of action of these compounds in targeting p21. All the chelators up-regulated p21 mRNA in the five tumor cell-types assessed. In contrast, examining their effect on total p21 protein levels, these agents induced either: (1) down-regulation in MCF-7 cells; (2) up-regulation in SK-MEL-28 and CFPAC-1 cells; or (3) had no effect in LNCaP and SK-N-MC cells. The nuclear localization of p21 was also differentially affected by the ligands depending upon the cell-type, with it being decreased in MCF-7 cells, but increased in SK-MEL-28 and CFPAC-1 cells. Further studies assessing the mechanisms responsible for these effects demonstrated that p21 expression was not correlated with p53 status, suggesting a p53-independent mechanism. Considering this, we examined proteins that modulate p21 independently of p53, namely NDRG1, MDM2 and ΔNp63. These studies demonstrated that a dominant negative MDM2 isoform (p75(MDM2)) closely resembled p21 expression in response to chelation in three cell lines. These data suggest MDM2 may be involved in the regulation of p21 by chelators.

摘要

诸如2-羟基-1-萘甲醛异烟酰腙(311)和二-2-吡啶基酮-4,4-二甲基-3-硫代半卡巴腙(Dp44mT)等螯合剂靶向肿瘤细胞的铁池并抑制其增殖。这些药物还能调节多个靶点,其中之一是细胞周期蛋白依赖性激酶抑制剂p21。因此,本研究探讨了这些化合物靶向p21的作用机制。在评估的五种肿瘤细胞类型中,所有螯合剂均上调了p21 mRNA。相比之下,在检测它们对总p21蛋白水平的影响时,这些药物产生了以下不同结果:(1)在MCF-7细胞中下调;(2)在SK-MEL-28和CFPAC-1细胞中上调;或(3)在LNCaP和SK-N-MC细胞中无影响。p21的核定位也因配体不同而受到不同影响,具体取决于细胞类型,在MCF-7细胞中降低,但在SK-MEL-28和CFPAC-1细胞中增加。进一步评估这些效应背后机制的研究表明,p21表达与p53状态无关,提示存在一种不依赖p53的机制。考虑到这一点,我们检测了独立于p53调节p21的蛋白质,即NDRG1、MDM2和ΔNp63。这些研究表明,一种显性负性MDM2异构体(p75(MDM2))在三种细胞系中对螯合作用的反应与p21表达极为相似。这些数据表明MDM2可能参与了螯合剂对p21的调控。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验